

Instructions to authors

Submission procedure. Submission of a paper to *European Psychiatry* is understood to imply that the data contained therein has not previously been published (except in abstract form) or is being considered for publication elsewhere.

There are no submission or page charges.

Only submissions in English will be considered. One original plus three copies (one set of photographs must be original prints) should be submitted to one of the following *five receiving centres* according to geographical location:

Pr C BALLUS
Unidad de Psiquiatria
Facultad de Medicina
Casanova, 143
08036 Barcelona, Spain
Fax: (34) 32 54 66 91

Pr M MAJ
Universita di Napoli
Ist di Psichiatria
Largo Madonna delle Grazie
80138 Napoli Italy
Fax: (39) 81 44 99 38

Pr JD GUELF
Clinique de la Faculté
100, rue de la Santé
75674 Paris Cedex 14 France
Fax: (33) 1 45 65 89 43

Pr CB PULL
Centre Hospitalier de Luxembourg
4, rue Barblé
1210 Luxembourg
Fax: (352) 45 87 62

Pr H HEIMANN
Goethestrasse 23
7400 Tübingen Germany
Fax: (49) 70 71 29 41 41

Pr M ACKENHEIL
Psychiatrische Klinik
und Poliklinik
der Universität München
Nussbaumstr 7
8000 München 2 Germany
Fax: (49) 89 51 60 47 41

Pr RM MURRAY
Institute of Psychiatry
De Crespigny Park
London SE5 8AF UK
Fax: (44) 71 70 35 796

Dr P BECH
Dept of Psychiatry
Frederiksborg General Hospital
DK-3400 Hillerød Denmark
Fax: (45) 48 24 20 16

Deputy Editors

Dr P BOYER
Inserm, Clinique des maladies
mentales et de l'encéphale
100, rue de la Santé
75014 Paris
Fax: (33) 1 45 65 89 43

Dr Y LECRUBIER
Hôpital de la Salpêtrière
Pavillon Clérambault U 302
47, boulevard de l'Hôpital
75651 Paris Cedex 13
Fax: (33) 1 45 85 28 00

Submissions from Eastern Europe should, for the time being, be sent to the Deputy Editors.

Submissions from non European countries can be sent to any of the preceding Editors.

Papers that do not conform to the general criteria for publication in *European Psychiatry* will be returned immediately to authors to avoid unnecessary delay in submission elsewhere.

Organisation of the manuscript. Manuscripts should be typewritten/printed double-spaced with wide margins throughout. Title page, abstracts, tables, legends to figures and reference list should each be provided on separate sheets of paper. The title page should include: the title, the name(s) and affiliation(s) of the author(s), an address for correspondence, and telephone/fax numbers for editorial queries. All original and review articles should include an abstract (a single paragraph of no more than 150 words) and 3-6 key words for abstracting and indexing purposes. For original and review articles, the text should be ordered under the following headings: Introduction, Subjects and methods/Materials and methods, Results, Discussion (may be combined with Results), Conclusion, Acknowledgments (when appropriate), References.

• **Short communications** should not exceed 1 500 words or the equivalent space including figures and tables, with abstracts of no more than 50 words.

• **Rapid communications** should not exceed 1 000 words or the equivalent space. The summary should consist of no more than 50 words. Only one table and one figure are accepted. Figures (glossy) should be submitted in a form suitable for direct reproduction. References should be limited to a maximum of 10 and are in addition to the 1 000 words. To ensure rapid publication, articles must meet a high standard, both in terms of scientific content and presentation. Following acceptance of an article in this category, no further modifications by the author will be allowed. Rapid communications are considered to be articles comprising preliminary but consistent results and will be published within three months following acceptance.

• **Letters to the Editor** (maximum of 500 words) will be processed rapidly and therefore should be sent to the Deputy Editors. To ensure speedy publication, please adhere strictly to the general instructions on style and arrangement; provide only figures and tables suitable for direct reproduction.

• **Illustrations.** Photographs should be presented as glossy prints with high contrast. Figures should be completely and consistently lettered, the size of the lettering being appropriate to that of the illustration, taking into account the necessary reduction in size. Illustrations should be designed to fit either a single column or the full text width. Each illustration should be clearly marked on the reverse side with the name of the author(s), the number of the illustration and its orientation (top).

Colour figures will be included subject to the author's agreement to defray part of the cost.

• **Tables.** All tables must be cited in the text, have titles and be numbered consecutively with roman numerals. Only horizontal lines should be included, and kept to a minimum.

• **References** (Vancouver). Authors are responsible for the accuracy of the references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the text. In the text, a reference should be cited by author and date; when there are more than two authors, state the first author's name followed by 'et al'. References should be arranged alphabetically at the end of the paper and include, in the following order: all authors (surnames followed by initials), title of article, journal title (abbreviated according to the Serial Sources for the Biosis Data Base), year of publication, volume number, and inclusive page numbers.

For a book, the editor's names, book title, publisher and publisher's location should appear before volume and page numbers.

Examples:

Journal article

Lão H, Rein W, Souche A, Dufour H, Guelfi JD, Malka R, Olié JP. Psychopathological and sociodemographic characteristics of 1231 depressed patients with and without co-existing alcoholism. *Psychiatr & Psychobiol* 1990;5:249-56

Book

Takahashi R, Flor-Henry P, Gruzelier J, Niwa SI. *Dynamics, Laterality and Psychopathology*. Amsterdam: Elsevier, 1987

Chapter in a book

Pinard G, Tetreault L. Concerning semantic problems in psychological evaluation. In: Pichot P, ed. *Psychological Measurements in Psychopharmacology. Modern Problems in Pharmacopsychiatry*. Basel: Karger, 1974; 7:8-22

• **Nomenclature.** Metric units must be used throughout, laboratory units must be followed by SI units. The generic name of a drug should be used unless the specific trade name of the drug is directly relevant to the discussion.

• **Proofs and reprints.** Proofs will be sent to the author indicated on the title page; no changes to the original manuscript will be allowed at this stage. They should be carefully corrected and returned (preferably by fax) to the publisher within 48 hours after reception. If this period is exceeded, the galleys will be proofread by the editorial staff of the publishing house only and printed without the author's corrections.

25 free reprints are supplied per contribution. Additional reprints may be ordered at the prices quoted on the order form sent to the corresponding author.

• **Copyright.** As soon as the article is published, the author is considered to have transferred his rights to the publisher. Requests for reproduction should be sent to the latter.



TRAITEMENT DE L'INHIBITION ET DU BLOCAGE DU COMPORTEMENT

PRAZINIL

CARPIPRAMINE



Forme et présentation : Etui de 24 comprimés sécables dosés à 50 mg de carpipramine (DCI) base sous forme de dichlorhydrate monohydraté. **Propriétés :** Psychotrope désinhibiteur. **Indications :** • Inhibition au cours des états anxieux. • Les psychoses schizo-phréniques à symptomatologie déficitaire, qu'il s'agisse de psychoses déficitaires d'emblée (forme hétérophréniques, schizo-phréniques simples) ou de déficit progressif survenant au cours de l'évolution des psychoses chroniques. **Contre-indications :** • Troubles de la conduction et du rythme cardiaque. • Ne pas associer aux IMAO ; respecter un délai de 15 jours après l'arrêt d'un traitement comportant ce type de médicament. • Affections hépatiques et rénales sévères. • Grossesse ; chez une espèce animale, l'expérimentation met en évidence à très forte dose une embryotoxicité. Dans l'espèce humaine, le risque n'est pas connu ; par conséquent, par mesure de prudence, éviter de prescrire pendant la grossesse. • L'allaitement est déconseillé pendant le traitement. • Effets sur la capacité de conduire des véhicules ou d'utiliser des machines. **Précautions d'emploi :** • Surveillance en début de traitement (psychique et somatique) notamment chez les patients avec risque suicidaire. • Surveillance renforcée chez les épileptiques. • Surveillance particulière en cas d'anesthésie générale. • A utiliser avec précautions en cas d'affection cardio-vasculaire grave, d'insuffisance rénale et/ou hépatique. **Interactions médicamenteuses :** Association déconseillée avec l'alcool. **Associations à prendre en compte :** • Antihypertenseurs ; effet antihypertenseur et risque d'hypotension orthostatique majorés. Captopril et Enalapril ; effet antihypertenseur et risque d'hypertension orthostatique majorés. • Autres déprimeurs du système nerveux central ; majoration de la dépression centrale pouvant avoir des conséquences importantes, notamment en cas de conduite automobile ou d'utilisation de machines. **Effets indésirables :** • Quelques cas de difficultés d'endormissement ont été rapportés. • Possibilité d'hypotension orthostatique (en particulier chez le sujet âgé). • Très rares cas de galactorrhée et surdosage massif ; procéder à l'évacuation rapide du produit ingéré, hospitaliser le patient en milieu spécialisé. Il n'existe pas d'antidote spécifique. Liste I. A.M.M. 320 437.0 (1976). **Prix : 62,10 F (24 comprimés). Remboursé Sécurité Sociale à 65%. Admis aux Collectivités.**